Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy.

NCT04796194 is registered in ClinicalTrials.gov with Lytix Biopharma AS as lead sponsor.

NCT NCT04796194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04796194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy.
Lead sponsor
Lytix Biopharma AS
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2021
Completion date
July 1, 2025
Enrollment
23 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma